There remains a large unmet need for a safe, well-tolerated and effective therapy for idiopathic pulmonary fibrosis (IPF) that improves pulmonary function, delays disease progression, and reduces mortality. Admilparant (BMS-986278), a lysophosphatidic acid receptor 1 antagonist, is an orally (per os [PO]) administered investigational product being developed for the treatment of patients with IPF and progressive pulmonary fibrosis (PPF). A Phase 2 study in participants with lung fibrosis (Study IM027040) has shown favorable safety and efficacy with admilparant as monotherapy and in participants on antifibrotic therapy and supports the continued development of admilparant as a potential treatment for IPF.
